Publication | Open Access

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Metabolic SyndromeDeclare–timi 58Diabetes ManagementRenal DiseaseChronic Kidney DiseaseDiabetesType 2Diabetic Kidney DiseaseKidney DiseaseDiabetes ComplicationsDiabetes MellitusMedicineNephrology